Musculoskeletal Diseases

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Nervous System Diseases

Contracture

Dupuytren Contracture

Joint Diseases

Muscular Diseases

Fibroma

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Connective Tissue Diseases

Xiaflex surgery

Daniel Herren, Dr. med.

The purpose of this study is the validation of the Brief Michigan Hand Questionnaire by patient with Morbus Dupuytren and to build up a register.

examination of the characteristics of Patient with Morbus Dupuytren and the psychometric properties of the Brief Michigan Hand Questionnaire by this patients

Registry of Patient With M. Dupuytren and Validation of the Brief MHQ

Buildup of a Registry of Patient With M. Dupuytren and Validation of the Brief Michigan Hand Questionnaire

Measuring pain with the Numeric rating scale

Measuring grip strength with the dynamometer

Patient reported outcome measurement by arm, shoulder and hand disorders

Patient reported outcome measurement by hand disorders

Measuring the joint mobility of the fingers with the goniometer

Schulthess Klinik

Dr. med. Daniel Herren

Symptoms and General Pathology

Breast Neoplasms

Recurrence

Fatigue

500 mg PG2 injection will be administered to this group once per week for 8 weeks.

Placebo injection will be administered to this group once per week for 8 weeks.

PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.

PG2 Lyo. Injection 500mg

0.9% normal saline 500ml will be administered weekly for 8 weeks.

Placebo 0.9% normal saline

Tim Teng-Hsu Wang, PhD

Wei-Wu Chen, MD

The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.

The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies. The primary endpoint is to examine whether PG2, compar ed with placebo, can successfully reduce patients' fatigue (observed via prorated area under the curve \[AUC\] for the Brief Fatigue Inventory \[BFI\] scores) when primed with PG2 for 8 weeks during their chemotherapy. The other efficacy endpoints including th e time course change of patient reported BFI, fatigue improvement response rate (fatigue improvement response is defined as those with at least 10% reduction from baseline in the total BFI scores) after 8 weeks, self perceived improvement, hematological improvement, health related quality of life, and safety profiles will also be assessed between treatment arms and compared with the baseline.

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

A Phase II, Double Blind, Randomized, Placebo-controlled Study of PG2 Injection for the Treatment of moderate-to Severe Fatigue in Patients With Locally Advanced, Recurrent, or Metastatic Breast Cancer Who Are Receiving Infusional Chemotherapy

The prorated AUC for the global BFI score (average scores of 9 items), usual fatigue (item2) and worst fatigue (item 3) will be compared between PG2 and the placebo arms at the end of the study.

FIRR is defined as those with at least 10% reduction from baseline in the total BFI scores after 8-week treatment. 20% and 30% reduction will also be evaluated.

PhytoHealth Corporation

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Blood and Lymph Conditions

Rare Diseases

Kidney Diseases

Kidney Failure, Chronic

Renal Insufficiency

Anemia

Renal Insufficiency, Chronic

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Anti-Inflammatory Agents

Antirheumatic Agents

Analgesics

All Drugs and Chemicals

Hematinics

Chrysarobin

Epoetin Alfa

Single injection administered intravenously

Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.

Single peginesatide dose of 0.05 mg/kg administered intravenously.

Single peginesatide dose of 0.10 mg/kg administered intravenously.

Placebo

peginesatide

Affymax

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

This was a Phase 1, double-blind, placebo-controlled trial of peginesatide, an erythropoiesis stimulating agent, with approximately 7 treatment cohorts and 7 healthy volunteer participants per cohort. In each cohort of 7 participants, a ratio of 5:2 participants was randomly assigned to receive a single dose of peginesatide or placebo, respectively, administered as an intravenous infusion. Planned peginesatide dose levels were to escalate by cohort. The study was conducted at a single clinical center.

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Registry of Patient With M. Dupuytren and Validation of the Brief MHQ	NCT01876498	Dupuytren Contr... Collagen Shrink... CRF	Xiaflex surgery	18 Years -	Schulthess Klinik
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients	NCT05440227	Cancer-related ...	PG2 Lyo. Inject... Placebo 0.9% no...	20 Years -	PhytoHealth Corporation
Registry of Patient With M. Dupuytren and Validation of the Brief MHQ	NCT01876498	Dupuytren Contr... Collagen Shrink... CRF	Xiaflex surgery	18 Years -	Schulthess Klinik
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers	NCT00097747	Anemia Chronic Kidney ... Chronic Renal F... Cancer	Placebo peginesatide	18 Years - 40 Years	Affymax

Spots Global Cancer Trial Database for crf

Every month we try and update this database with for crf cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for crf

Every month we try and update this database with for crf cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for crf cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.